Medasense Biometrics Ltd. announced today that it has received CE mark approval for its novel Pain Monitoring Device, PMD200™.
This new technology is now available to help physicians objectively assess a patient’s pain in critical care situations, where
patients are unable to communicate. This allows physicians to ensure pain is properly managed.
To read the full PR click here.